tx7b00227_si_001.pdf (803.14 kB)
Download fileMechanism of Error-Free DNA Replication Past Lucidin-Derived DNA Damage by Human DNA Polymerase κ
journal contribution
posted on 2017-10-03, 00:00 authored by Oliver
P. Yockey, Vikash Jha, Pratibha P. Ghodke, Tianzuo Xu, Wenyan Xu, Hong Ling, P. I. Pradeepkumar, Linlin ZhaoDNA damage impinges on genetic information
flow and has significant
implications in human disease and aging. Lucidin-3-O-primeveroside (LuP) is an anthraquinone derivative present in madder
root, which has been used as a coloring agent and food additive. LuP
can be metabolically converted to genotoxic compound lucidin, which
subsequently forms lucidin-specific N2-2′-deoxyguanosine (N2-dG) and N6-2′-deoxyadenosine (N6-dA) DNA adducts. Lucidin is mutagenic and carcinogenic
in rodents but has low carcinogenic risks in humans. To understand
the molecular mechanism of low carcinogenicity of lucidin in humans,
we performed DNA replication assays using site-specifically modified
oligodeoxynucleotides containing a structural analogue (LdG) of lucidin-N2-dG DNA adduct and determined the crystal structures
of DNA polymerase (pol) κ in complex with LdG-bearing DNA and
an incoming nucleotide. We examined four human pols (pol η,
pol ι, pol κ, and Rev1) in their efficiency and accuracy
during DNA replication with LdG; these pols are key players in translesion
DNA synthesis. Our results demonstrate that pol κ efficiently
and accurately replicates past the LdG adduct, whereas DNA replication
by pol η, pol ι is compromised to different extents. Rev1
retains its ability to incorporate dCTP opposite the lesion albeit
with decreased efficiency. Two ternary crystal structures of pol κ
illustrate that the LdG adduct is accommodated by pol κ at the
enzyme active site during insertion and postlesion-extension steps.
The unique open active site of pol κ allows the adducted DNA
to adopt a standard B-form for accurate DNA replication. Collectively,
these biochemical and structural data provide mechanistic insights
into the low carcinogenic risk of lucidin in humans.